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In Sergio Leone’s classic western drama
“The Good, the Bad, and the Ugly” the final
scene depicts the three protagonists, each
with their specific personality trait and fast-
draw capability, assembled in a graveyard
for a shoot-out. The analogy is thus to
focal sites of inflammation, with different
subpopulations of myeloid cells assembled
within a tissue in proximity to each-other,
but with different functional phenotypes,
associated surface marker expression, and
enacting different functions. The basic
macrophage functional states are described
as pro-inflammatory, anti-inflammatory,
and wound healing, respectively. The M1
versus M2 phenotypic paradigm was first
coined to distinguish macrophage popula-
tions and has been instrumental in increas-
ing our knowledge of myeloid biology
(1). Despite more recent suggestions that
there is a continuum of activation states
between the extremes of M1- and M2-
type responses (2–4), this partly reflects
an over-emphasis on cell surface pheno-
types. We should now have the technolo-
gies to be able to assess the relevance of
specific cells within specific microenviron-
ments within a given healthy or diseased
tissue. The issue of functionality (irrespec-
tive of surface phenotype) and the con-
cept of functional diversity within distinct
microenvironments within a tissue have
been less studied, and is the focus of this
commentary.
Let us first consider in simplistic
terms three stages of an inflammatory
response (Figure 1A): the “Good” non-
inflammatory phase in which normal tis-
sue homeostasis is maintained by resident
macrophages (green arrows); the “Bad”
phase in which potentially tissue-damaging
macrophage functionality is initiated due
to damage, infection, or autoimmunity
(pro-inflammatory) or tumor develop-
ment (anti-inflammatory) (red); and the
“Ugly” phase representing a failure to
down-regulate the initial response that
results in chronic pathogenesis and tis-
sue damage (blue), i.e., an inability to
return to the “Good” phase through heal-
ing. The definition of “good” and “bad”
in this sense will depend on the setting –
a pro-inflammatory response to an infec-
tion may be desirable, but if uncontrolled
may lead to tissue damage. Likewise, while
anti-inflammatory responses beneficially
modulate autoimmune reactions, they con-
tribute to tumor development. The salient
point is that macrophage function will vary
during these different phases.
MICROENVIRONMENTAL VARIATION IN
INFLAMMATION
The aforementioned basic view reflects the
overall functionality of an inflamed tis-
sue, but does not take into account the
potential compartmentalization of a tissue,
and that these processes may be occur-
ring simultaneously in different areas of
the affected tissue. Consider the image
of a slice of multiple sclerosis subcorti-
cal white matter brain tissue (Figure 1B).
Luxol fast blue staining (left) reveals
healthy regions of myelin (dark blue),
focal areas of demyelination (red arrows),
and focal “shadow plaques” that repre-
sent remyelination (green arrows) (5). Two
disparate processes – pathogenic demyeli-
nation and healing remyelination, occur-
ring side-by-side, implicating that within
these physically separate microenviron-
ments immune cells such as macrophages
might be conducting different processes –
damage or repair (right image). In support
of this, recent histopathological evidence
reveals mixed macrophage phenotypes in
human MS lesions (6).
Understanding of the concept of spe-
cific microenvironments within tissues
is increasing, not least within tumor
immunology (7). The ambiguous role of
tumor associated macrophages (TAMs) in
tumor progression is reflected by TAMs
both actively augmenting cancer cell pro-
liferation, invasion, metastasis, and angio-
genesis by releasing cytokines, growth fac-
tors, enzymes, and angiogenic factors, but
they also kill cancer cells. These varied
activities encompass both M1 and M2
macrophage properties. It is counterintu-
itive that such diverse tumor-promoting, or
conversely anti-tumoral, activities are per-
formed by a single TAM cell type, so the
existence of distinct TAM subpopulations
associated with different intra-tumoral
microenvironments is predicted (8). The
source of the TAM may also influence their
functions. For example, in gliomas TAM
may be either resident brain microglia or
blood infiltrating macrophages. Molecu-
larly and functionally distinct TAM sub-
populations may thus coexist in tumors,
the heterogeneity depending on cancer
type, stage of tumor progression and spe-
cific location within the tumor tissue (9,
10). A dynamic“switch”in TAM phenotype
during tumor progression may explain
the mixed activation state of TAM sub-
sets present in different established tumors,
and in certain models a switch from TAM
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FIGURE 1 | (A)Temporal and microenvironmental macrophage functionality during immune activation.
(B) Left hand panel is reproduced, with permission, from Adams, C. W. M. A Colour Atlas of Multiple
Sclerosis and Other myelin Disorders (©1989 Wolfe Medical Publications Ltd.).
is linked to tumor progression (11). It
is noteworthy that the “switch” that is
often referred to in the literature may
rather reflect a relative predominance in
M1 or M2 cell numbers rather than a
full phenotypical/functional change of a
single cell. Different macrophage popu-
lations induced during tumor progres-
sion have also been reported to occupy
different microenvironments within the
tumor mass (12). In a murine hepatocel-
lular carcinoma model, the MHC Class
IIhigh TAM population (M1-like) was asso-
ciated with tumor growth suppression dur-
ing early tumor growth while MHC IIlow
TAMs (M2-like) dominated as the tumor
progressed (13).
Investigation of the spatial distribu-
tion of macrophage phenotypes in human
plaques at different stages of atheroscle-
rosis development also reveals microenvi-
ronment variations. M1 is the predomi-
nant phenotype in rupture-prone shoulder
regions, and M2 in the adventitia (14).
Likewise, in models of lung inflamma-
tion induced by butylated hydroxytoluene
or Mycobacterium tuberculosis there is an
initial M1 activation that progresses to
M2 (15). However, granuloma-associated
macrophages during active infection may
retain an M1 phenotype while nearby
uninfected alveolar macrophages are M2.
Clearly, at various sites of inflammation
then individual subpopulations of cells
contribute to specific microenvironments
in different ways.
INFLAMMATION IS A TEMPORALLY
EVOLVING CIRCUMSTANCE
Another aspect to consider when homog-
enizing tissues for cell purification and
subsequent FACS or RT-PCR analyses is
not only the geographical gradient of
macrophage activation states that will be
lost but also a temporal element. For
example, given the realization that resident
macrophages and circulating monocytes
are fundamentally different cell types (16,
17), consider the macrophage disappear-
ance reaction (18) in which initial immune
activation within a tissue results in efflux
of resident cells and infiltration of circulat-
ing cells, this cellular flux being reversed on
eradication of the offending stimulant. If
one would take a snapshot in the tissue and
sample the phenotype of the macrophages
present at a given time, it is difficult to
be sure whether they are coming or going
from the site of interest. Obviously, this can
impact on their functional relevance to the
ongoing immunological process and espe-
cially in our scientific interpretation. Now
that small rodent PET/CT/MRI imaging
is becoming more standardized, one can
expect this issue to be further addressed in
forthcoming years.
FUNCTION VERSUS FORM DURING
INFLAMMATION
A host requires basic macrophage functions
in order to survive. These functions are
sometimes less easily measured than other
surrogate markers such as cell surface pro-
teins. Consequently, there is a wide range of
surface markers, cytokines and chemokines
reported to distinguish M1 and M2 acti-
vation states (mostly in vitro). However,
the use of such “markers” without paral-
lel assessment of functions can result in
conflicting results.
Variation in published results might
be explained by variation in employed
activation protocol, difference in rodent
strain (19) or human donor to which the
same protocol is applied. Take IL-10, for
example, a prototypic anti-inflammatory
cytokine that can be produced by M2 and
M1 cells. Both the production and lack of
production of IL-10 in M-CSF-stimulated
human M2 monocytes have been described
(21). Reliance on surface marker expres-
sion can also be particularly misleading –
if anti-inflammatory M2 states receive an
additional LPS stimulation in vitro, then
while expression of CD86 and MHC II
might become upregulated (“M1”) the IL-
10 production is actually enhanced (22).
Given the dominant functional role of IL-
10 as an immunosuppressive cytokine, then
functionally such cells are more potent
M2, despite starting to develop an M1
surface. Similarly, in alcoholic hepatitis,
liver M2 macrophages were determined to
express M1-associated receptors (23). It
would thus seem that there is a necessity to
distinguish between surface and functional
phenotypes.
Clearly, the biological functions in
microenvironments should be more
important than any other phenotype, and
one expects as much functional varia-
tion as there is in M1–M2 phenotypic
definition. Even the basic morphology of
activated cells in vitro is reported to be
exact for different phenotypes, yet closer
examination reveals this is not neces-
sarily the case (20, 24, 25). In our own
study in which we applied IL-4, IL-10,
and TGFβ simultaneously, cells of three
different morphologies were apparent in
the same culture well, representing the
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three distinct morphologies observed if
single cytokines were applied in separate
cultures (26). Does this imply microhetero-
geneity even in the cell culture medium
containing a mixture of cytokines, such
that the first cytokine receptor ligated
on a cell surface dictates the morphol-
ogy of that specific cell? Whether the
sequence of activation is of any conse-
quence will depend on whether there are
actually any kinetic effects that impinge
on the final morphology or function.
This may seem a trivial issue but a
recent publication elegantly demonstrated
precisely why this is important by study-
ing human macrophage transcriptomes
using different combinations of activation
stimulants (4).
The challenge is thus how to quan-
tify functional phenotypes in microenvi-
ronments. We have a limited range of
markers that can be applied immuno-
histologically. Detailed knowledge about
expression/regulation of expression for
each macrophage population in each tissue,
within each microenvironment within a tis-
sue, during both resting and inflammatory
states, is currently lacking. Development of
conditional knockout mouse strains lack-
ing resident/peripheral macrophage popu-
lations is one approach that is warranted,
for example, to distinguish the relative
roles of infiltrating macrophages and res-
ident microglia during brain tumor devel-
opment. Alternatively, the use of single
cell laser capture and proteomic or genetic
analyses might be one modern approach
to explore what individual cells within
a particular microenvironment do within
their niche, although function will only be
inferred from these analyses (27, 28). The
basic assumption is that all cells are equal
and that the relative numbers of different
subpopulations will ultimately define the
functional state of the tissue. Increasing
evidence challenges this assumption, and
in our hands co-culture of pre-activated
M1- and M2-type populations demon-
strated a clear dominant phenotype of
M2 cells (pre-activated with a combina-
tion of IL-4/IL-10/TGFβ) (29). Even if sin-
gle cells are phenotyped and their relative
numbers are quantified within a tissue or
microenvironment, it remains difficult to
predict the net functional activity or inter-
play in vivo if they are not functionally
equivalent.
THERAPEUTIC MANIPULATION OF
CHRONIC INFLAMMATORY
MICROENVIRONMENTS
A final question is whether chronic
inflammatory states such as autoimmune
diseases represent a failure to down-
regulate pro-inflammatory M1-mediated
tissue destruction (i.e., a deficiency in anti-
inflammatory M2 function), or whether
this reflects a lack of healing M2 function-
ality. It follows that a stochastic alteration
of the relative M1/M2 functions within
microenvironments represents a feasible
therapeutic approach. Earlier work indi-
cated that M2 cells accumulate at the
edge of the tissue damage in the setting
of spinal cord injury (30). If large num-
bers of “therapeutic cells” could be applied
to inflammatory microenvironments (e.g.,
through local stimulation or cell trans-
fer) then they should be able to exert tai-
lored “local” immunomodulatory effects.
In our experience adoptively transferred
pre-activated anti-inflammatory M2 cells
resulted in clinical abrogation of both T1D
(22) and MOG-EAE (26) disease courses.
In addition to a cell therapy approach,
there are new generations of agents aimed
at specific conversion of macrophage phe-
notypes within microenvironments, such
as TAM conversion to M1 within tumors
using docetaxel and phosphatidylserine-
targeting antibody (31). The effectiveness
of this approach was first reported many
years ago (32). The major challenge will
be to access the microenvironments specif-
ically rather than systemically administrat-
ing an agent and hoping for its specific
access to the target area.
LOOKING BACK AND LOOKING AHEAD
The last decade has heralded a revolution
in our understanding of immune mecha-
nisms and particularly the critical role of
macrophages in both innate and adaptive
responses. During the coming decade, we
can expect a refinement of this knowl-
edge when the functions of individual
cells and their specific contributions to a
specific microenvironment become better
understood. This may lead to yet further
refinement of macrophage nomenclature
as function supersedes form in impor-
tance. The next era may well also her-
ald the successful therapeutic manipula-
tion of inflammatory microenvironments
in order to slow or abrogate inflammatory
disease courses in human beings. One can
be certain that the good macrophages van-
quishing the bad macrophages will be a
component aspect, and that restoration
of the damaged, ugly tissue will also be
macrophage-dependent.
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